Browsing Tag
Foresite Capital
4 posts
Biogen is paying up to $1bn for preclinical optionality. What does RayThera really add?
Biogen's $1 billion RayThera deal expands its immunology pipeline and raises fresh capital allocation questions. Read what BIIB investors should watch next.
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million…
ALX Oncology raises $105m to advance clinical development of ALX148
ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity…
Element Biosciences raises $80m for genomic sequencing solutions
Californian biotechnology startup Element Biosciences, which focuses on developing genomic sequencing solutions for research and diagnostic markets, has…